BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18559597)

  • 1. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Zlotta AR; Perrotte P; Suardi N; Saad F; Karakiewicz PI
    J Clin Oncol; 2008 Mar; 26(9):1526-31. PubMed ID: 18349404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
    Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
    J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
    Svatek RS; Jeldres C; Karakiewicz PI; Suardi N; Walz J; Roehrborn CG; Montorsi F; Slawin KM; Shariat SF
    Prostate; 2009 Jun; 69(8):886-94. PubMed ID: 19229851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
    Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
    J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
    J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
    Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
    Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
    Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy.
    Chun FK; Briganti A; Jeldres C; Gallina A; Erbersdobler A; Schlomm T; Walz J; Eichelberg C; Salomon G; Haese A; Currlin E; Ahyai SA; Bénard F; Huland H; Graefen M; Karakiewicz PI
    Eur J Cancer; 2007 Feb; 43(3):536-43. PubMed ID: 17222546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
    Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
    BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
    Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
    Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
    Reeves JR; Dulude H; Panchal C; Daigneault L; Ramnani DM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6018-22. PubMed ID: 17062675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.